Je viens de voir un article de « The American Journal of Medecine » publié le 1er janvier 2021 qui parle entre-autre du traitement Hydroxychloroquine + Azithromycine pour traiter les patients atteints de COVID19. Ils parlent de résultats d’essais randomisés.
L’article complet se trouve ici :
https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltext
Voici un extrait :
Hydroxychloroquine (HCQ) is an antimalarial/anti-inflammatory drug that impairs endosomal transfer of virions within human cells. HCQ is also a zinc ionophore that conveys zinc intracellularly to block the SARS-CoV-2 RNA-dependent RNA polymerase, which is the core enzyme of the virus replication.
The currently completed retrospective studies and randomized trials have generally shown these findings: 1) when started late in the hospital course and for short durations of time, antimalarials appear to be ineffective, 2) when started earlier in the hospital course, for progressively longer durations and in outpatients, antimalarials may reduce the progression of disease, prevent hospitalization, and are associated with reduced mortality.
In a retrospective inpatient study of 2541 patients hospitalized with COVID-19, therapy associated with an adjusted reduction in mortality was HCQ alone (hazard ratio [HR] = 0.34, 95% confidence interval [CI] 0.25-0.46, P <0.001) and HCQ with azithromycin (HR = 0.29, 95% CI 0.22-0.40, P <0.001).
Pour résumé, ce traitement serait efficace si il est pris tôt.
Ça ne vous rappelle pas ce que disait un certain professeur depuis le début de l’épidémie ?